News Release
FOR IMMEDIATE RELASE
December 17, 2014

FOR MORE INFORMATION
Julie-Ann Cabana
(913) 696-1601
jcabana@vinceandassociates.com

Dyax Corp.'s First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the *Annals of Allergy, Asthma & Immunology*

Overland Park, KS – Vince & Associates Clinical Research, a premier provider of early phase clinical research services to the global biopharmaceutical industry, announced the release of the print publication of scientific data for Dyax Corp.'s (Dyax) DX-2930 monoclonal antibody in a first-in-human study in the *Annals of Allergy, Asthma & Immunology*.

The paper describes the results from the first-in-human clinical study of DX-2930 which met all of its objectives of assessing safety, tolerability and pharmacokinetics of this investigational drug candidate. Additionally, the data indicate that DX-2930 has a half-life of 17-21 days in humans. DX-2930 is being developed for the prophylactic treatment of hereditary angioedema (HAE) attacks and is currently being evaluated in a Phase 1b study in patients with HAE. The complete publication can be accessed online www.annallergy.org/article/S1081-1206(14)00377-9/pdf.

"Our clinical research partners play an integral role in the DX-2930 development program," said Ryan Iarrobino, Senior Director, Clinical Development at Dyax. "Vince & Associates has expertise in early-stage human trials, state-of-the-art facilities, and excellent capabilities with subject recruitment and retention, all important qualities that we look for in our collaborators."

Dr. Brad Vince, CEO and Medical Director at Vince & Associates, commented: "It is essential for Vince & Associates to work with companies that are at the forefront of drug discovery such as Dyax as it enables our organization to support important research and development initiatives for promising new therapies."

Vince & Associates offers clinical pharmacology expertise to support monoclonal antibody development plans especially when entering into Phase I clinical trials. Clinical trials for biologics require experience and specialty knowledge. Immunogenicity, rare adverse events, and efficacy are all factors to take into consideration when developing a biologic.

About Vince & Associates Clinical Research
Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for 15 years. The research professionals at Vince & Associates are proud to be recognized in the industry as a "Center of Research Excellence."

- more -

Vince & Associates currently operates a state-of-the-art, multimillion-dollar, 100-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This early development unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

About Altasciences

Altasciences is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithme Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information

Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at www.vinceandassociates.com.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company currently markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE and is developing DX-2930, a fully human monoclonal antibody, for the potential prophylactic treatment of HAE. Additionally, Dyax has broadly licensed its phage display technology and has a portfolio of product candidates being developed by multiple licensees that it refers to as the Licensing and Funded Research Portfolio.

For additional information about Dyax, please visit www.dyax.com.

For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

# # #